Low frequency of drug-drug interactions (DDIs) with the novel all oral antivirals elbasvir (EBV) and grazoprevir (GRZ) in patients with HCV genotype 1 infection in German real-wor…
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, P Geyer, B Weber, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2016 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background: The effectiveness of HCV treatment has dramatically improved with the approval of direct-acting antivirals (DAAs). However, a high frequency of clinically relevant DDIs between the regular outpatient medications and DAAs has been reported for HCV treatment with sofosbuvir in combination with simeprevir, daclatasvir or ledipasvir (30%-40%) while patients (pts) treated with ombitasvir/paritaprevir/ritonavir ± dasabuvir had a risk > 60% (Clin Infect Dis 2016;62: 561 – 567). Recently, the NS3/4a protease inhibitor GRZ in combination with the NS5A polymerase inhibitor EBV has been shown to be highly effec…
